SVS:CA

Solarvest Launches World's First Organic DHA Omega-3 Fruit Gummy Drops for Children

(TheNewswire)



TheNewswire - December 21 st, 2020  -  Solarvest BioEnergy Inc. ("Solarvest", or the "Company") (TSXV:SVS), Solarvest, through it's 100% wholly owned subsidiary Eversea TM is pleased to announce plans to launch its Organic Omega-3 nutritional Gummy Fruit Drops for children after the year-end holiday break.  The fruit drop has been produced and passed quality control under high standards from our German contract manufacturer.  The final phase is to confirm the quality of the product after the logistics of shipping and packaging which is underway.  The Company's first of its kind nutritional gummy product will be an exceptional competitor in the large and rapidly growing gummy supplement market.  The organic gummy contains Solarvest's proprietary, certified organic, Omega-3 DHA powder, a sustainable, plant based powder designed for organic, vegetarian and vegan consumers.

The Company is actively working to add unique products to satisfy the demand for premium organic, Omega-3 and plant-based health products.  This first labelled product will soon commence sales in the USA and be available from the company's E-commerce web site ( www.eversea.ca ) and through Amazon. Eversea will be capable of providing organic oriented retailers with house branded products based on our patented ingredient (differentiation), so that they may take benefit from the extensive market demand for the product's unique characteristics, particularly for organic and vegan diets.

The company also announces the completion of its USA infrastructure and logistics system for order processing. Our west coast distribution point is located close to the primary and most important market for organic and plant based supplements/foods.  In addition this strategic location is close to organic food processors, sustainable oriented consumers and the organic baby food market.  The facility is capable of nation-wide distribution.

The Eversea Omega-3 powder is USDA and EU Organic Certified and produced from the Company's sustainable, proprietary process.  Gerri Greenham, CEO, notes that, "Our omega 3's are sustainable because they are expressed in algae and grown in controlled facilities which eliminates the need to harvest marine species.  Our technology produces an organically certified, highly bioavailable long-chain Omega-3 that cannot be produced by common plant species such as flaxseed or hemp which only contain ALA Omega-3.  Our customers are buying a product to improve health so they want an organic product which has a clean label of ingredients."  The Company also intends to sell the powder supplement to organic food processors and marketers, such as baby food suppliers, to facilitate the development of enhanced patent-protected products. The Company also intends to pursue other premium animal health applications such as high Omega-3 eggs, pet supplements and food. "

Eversea has also initiated a second product run with its German-based organically certified manufacturer to supplement inventory levels domestically and initiate international sales. Recognizing that Eversea's organically certified product holds a competitive advantage with several differentiating factors focused on sustainability, environmental conservation, bioavailability and purity, the Company will be able to deliver alternatives for the adult, seniors, infant formula and maternity markets to complement its adolescent offering.

Market Overview

"The EPA and DHA omega-3 finished product market size reached US$44.2 billion in 2019. as stated in the  2020 Global EPA &DHA Finished Goods Report.  Market dynamics and new product development are driving increased growth in certain product categories and across several regions of the world, leading the global EPA and DHA consumer product market to a projected annual growth rate of 6.1% for 2020–2021".

"The global gummy vitamins market size is estimated to be valued at USD 5.9 billion in 2020 and projected to reach USD 10.6 billion by 2025, recording a CAGR of 12.5%, in terms of value" as stated by Reportlinker in Oct 27, 2020 PRNewswirepress release.

About Solarvest

Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The company has successfully demonstrated the expression of BMP, a high value therapeutic protein, viral antigens (immune stimulating proteins), and Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:

Email: invest@solarvest.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties.  Actual events or results could differ materially from the Company's expectations and projections.

Copyright (c) 2020 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

The Conversation (0)

AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 to all stockholders of record as of the close of business on February 14, 2025 .

About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
CLEO Further Expands Ovarian Cancer Trial with Siles Health

CLEO Further Expands Ovarian Cancer Trial with Siles Health

Cleo Diagnostics (COV:AU) has announced CLEO Further Expands Ovarian Cancer Trial with Siles Health

Download the PDF here.

BLINCYTO® ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96%

Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA

Investment Establishes Second Facility in Holly Springs ; Builds on Previous $550M Commitment

Amgen (NASDAQ: AMGN) today announced a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina . This brings the company's total planned investment in Holly Springs to more than $1.5 billion building on its previously announced $550 million commitment.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×